Science

GLP-1 and Inflammation Markers: CRP, IL-6, and What to Track

GLP-1 Companion · 7 min read

One of the most clinically significant findings to emerge from large GLP-1 medication trials is the consistent, substantial reduction in inflammatory markers — and the evidence that some of this anti-inflammatory effect is independent of weight loss. For patients who have been told their CRP is elevated or who have cardiovascular risk factors, this is a meaningful and trackable benefit of GLP-1 therapy.

Why Inflammation Markers Matter

Chronic low-grade inflammation is a central driver of atherosclerosis, insulin resistance, type 2 diabetes, certain cancers, and many other conditions associated with metabolic disease and aging. Elevated circulating inflammatory markers — particularly high-sensitivity C-reactive protein (hs-CRP) — are independent predictors of cardiovascular events, including heart attack and stroke.

The JUPITER trial established that statin therapy reduced cardiovascular events in people with elevated hs-CRP even when LDL cholesterol was not elevated, cementing CRP as a clinically actionable biomarker. GLP-1 medications reduce hs-CRP via multiple mechanisms, making them a meaningful tool for managing inflammatory cardiovascular risk.

CRP: The Primary Clinical Marker

C-reactive protein (CRP) is produced by the liver in response to inflammatory cytokines — primarily IL-6. It is the most widely measured and clinically validated inflammatory biomarker. In the SELECT trial — the landmark trial of semaglutide (Wegovy-dose) for cardiovascular risk reduction in over 17,000 patients — CRP was reduced by approximately 30 to 40 percent in the semaglutide group compared to placebo.

Crucially, this reduction was not fully explained by weight loss alone. Mediation analyses demonstrated that a portion of the cardiovascular benefit — and the CRP reduction — was attributable to direct anti-inflammatory effects of semaglutide, independent of the weight lost. This has substantial implications for how GLP-1 medications are understood: they are not simply weight loss drugs whose cardiovascular benefits are downstream of weight change. They appear to have direct anti-inflammatory activity.

hs-CRP vs. Standard CRP: Why the Distinction Matters

Standard CRP tests detect inflammation at clinically obvious levels — the kind that occurs during infections, acute injury, and overt flares of inflammatory disease. The range for cardiovascular risk assessment (below 3 mg/L) sits below the detection threshold of many standard CRP assays. High-sensitivity CRP (hs-CRP) uses a more sensitive detection method specifically designed to measure CRP in the range relevant for cardiovascular risk stratification.

IL-6: Upstream of CRP

Interleukin-6 (IL-6) is a cytokine (immune signaling molecule) that drives CRP production in the liver. It is secreted by macrophages, adipocytes (fat cells), and immune cells in response to infection, tissue damage, or metabolic stress. GLP-1 medications reduce IL-6 levels, and this upstream reduction is partly why CRP falls.

IL-6 is less commonly measured in routine clinical practice than CRP because it is more expensive and requires more specialized testing. For most patients, hs-CRP serves as a reliable downstream proxy for IL-6 and systemic inflammatory activity. However, in research contexts and in patients with specific inflammatory conditions (rheumatoid arthritis, cardiovascular disease with elevated CRP), IL-6 measurement provides additional information.

TNF-Alpha: The Master Inflammatory Cytokine

Tumor necrosis factor-alpha (TNF-alpha) is a powerful pro-inflammatory cytokine produced primarily by macrophages. It drives insulin resistance directly (by impairing insulin signaling in muscle and adipose tissue), promotes atherosclerotic plaque instability, and stimulates the production of other inflammatory cytokines in a cascade. Visceral adipose tissue is a major source of TNF-alpha secretion, which is why obesity is fundamentally pro-inflammatory.

GLP-1 medications reduce TNF-alpha through two mechanisms: weight loss reduces the adipose tissue mass that is producing it, and GLP-1 receptor activation on macrophages directly inhibits TNF-alpha production. TNF-alpha is not routinely measured in clinical practice but is an important part of the mechanistic picture of why GLP-1 medications have cardiovascular and metabolic benefits.

Adipose Tissue: The Inflammation Source

Visceral adipose tissue — the fat stored around abdominal organs — is not metabolically inert. It is an active endocrine organ that secretes a range of pro-inflammatory molecules called adipokines, including TNF-alpha, IL-6, IL-1 beta, and leptin in excess amounts. Visceral fat is more metabolically active and more inflammatory than subcutaneous fat. GLP-1 medications preferentially reduce visceral fat, which is why inflammatory marker reductions are disproportionate to the total weight lost.

A Practical Testing Protocol

1. At baseline (before or within weeks of starting a GLP-1 medication): obtain hs-CRP, complete metabolic panel (CMP), and lipid panel. This gives you a starting point for all key cardiovascular risk markers.
2. At 6 months: repeat hs-CRP and lipid panel. Most patients will see meaningful reductions in hs-CRP by this point. If CRP has fallen below 1.0 mg/L, this is in the low-risk range and an excellent sign.
3. Interpret results in context: hs-CRP can be transiently elevated by any acute illness or infection. If your result is unexpectedly high, repeat the test when you are well.
4. Target: hs-CRP below 1.0 mg/L is associated with low cardiovascular inflammatory risk. Between 1.0 and 3.0 mg/L is intermediate. Above 3.0 mg/L (in the absence of acute illness) is high risk and warrants discussion with your doctor.

A 30 to 40 percent reduction in CRP is not a side benefit of GLP-1 therapy — it is a direct, clinically meaningful reduction in the inflammatory burden that drives cardiovascular disease, independent of the pounds lost. Tracking it with an hs-CRP test is one of the simplest ways to quantify this benefit.

Sources

• Lincoff et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity. NEJM.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.